Adipokines and cardiovascular diseases: clinical and therapeutic value.

Prof. О.М. Korzh, Y.N. Fylenko.

 Kharkiv Medical Academy of Postgraduate Education.

The article considers the pathogenesis of hypertension and the background of adipokine imbalance. Adipokines are directly involved in the mechanisms of blood pressure, atherogenesis, regulation of oxidative stress, blood clotting and the development of non-infectious inflammation. Despite the wide range of antihypertensive drugs on the pharmaceutical market, achieving the target blood pressure level remains a challenge. The main problem in the treatment of hypertension is the development of resistance to pharmacotherapy in patients. In the pathogenesis of the development of resistant hypertension, hyperproduction of adipokines and proinflammatory cytokines with increased rigidity of the main vessels plays an important role. That is why adipokines can be the implementers of the mechanism of adverse effects on the cardiovascular system. Studying their pathophysiological role may make them a therapeutic target in the fight against cardiovascular disease.

Key Words: adipokines, hypertension, cardiovascular diseases, atherosclerosis, leptin, resistin, omentin, visfatin.


For citing:

  1. Корж, А.Н. Адипокины и сердечно-сосудистые заболевания: клиническое и терапевтическое значение / А.Н. Корж, Я.Н. Филенко // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2020. – № 2. – С. 47-53. doi: 10.15407/internalmed2020.02.047.
  2. Korzh ОМ, Fylenko YN. [Adipokines and cardiovascular diseases: clinical and therapeutic value]. Shidnoevr. z. vnutr. simejnoi med. 2020;2:47-53. Russian. doi: 10.15407/internalmed2020.02.047.


  1. Statsenko M, Derevyanchenko M. The state of the main arteries, vascular age in patients with arterial hypertension and obesity: the role of leptin and adiponectin. Russian Journal of Cardiology. 2019;(1):7-11.
  2. Aroor A, Mandavia C, Sowers J. Insulin Resistance and Heart Failure. Heart Failure Clinics. 2012;8(4):609-617.
  3. Himion LV, Rybitskaya MO. Correction of cardiovascular risk factors in patients with type 2 diabetes mellitus. Family medicine: scientific-practical. 2016;2:90-92.
  4. Chazova IE, Ratova LG, Boitsov SA. Diagnosis and treatment of arterial hypertension. Recommendations of the Russian Medical Society for Arterial Hypertension and the All-Russian Scientific Society of Cardiologists. 2010;3:5-6.
  5. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc. 2014 Mar 4;3(2):e000582. doi: 10.1161/JAHA.113.000582. PMID: 24595191; PMCID: PMC4187500.
  6. Brown N, Zhou Z, Zhang J, Zeng R, Wu J, Eitzman D, Chen Y, Chang L. Perivascular Adipose Tissue in Vascular Function and Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(8):1621-1630.
  7. Villacorta L, Chang L. The role of perivascular adipose tissue in vasoconstriction, arterial stiffness, and aneurysm. Hormone Molecular Biology and Clinical Investigation. 2015;21(2):137-147.
  8. Saxton S, Withers S, Heagerty A. Emerging Roles of Sympathetic Nerves and Inflammation in Perivascular Adipose Tissue. Cardiovascular Drugs and Therapy. 2019;33(2):245-259.
  9. Ahmad M, Ferland D, Ayala-Lopez N, Contreras G, Darios E, Thompson J, Ismail A, Thelen K, Moeser A, Burnett R, Anantharam A, Watts S. Perivascular Adipocytes Store Norepinephrine by Vesicular Transport. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(2):188-199.
  10. Mallamaci F, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tripepi R, Zoccali C. Gender-dependent differences in plasma leptin in essential hypertension. American Journal of Hypertension. 2000;13(8):914-920.
  11. Makris T, Hatzizacharias A, Krespi P, Chronakis E, Vythoulkas J, Maria K, Tsoukala C, Votteas V. Markers of risk in young offspring with paternal history of myocardial infarction. International Journal of Cardiology. 2003;89(2-3):287-293.
  12. Piatti P, Di Mario C, Monti L, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A. Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation. 2003;108(17):2074-2081.
  13. Schnabel R, Messow C, Lubos E, Espinola-Klein C, Rupprecht H, Bickel C, Sinning C, Tzikas S, Keller T, Genth-Zotz S, Lackner K, Munzel T, Blankenberg S. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. European Heart Journal. 2008;29(5):649-657.
  14. Aghamohammadzadeh R, Greenstein A, Yadav R, Jeziorska M, Hama S, Soltani F, Pemberton P, Ammori B, Malik R, Soran H, Heagerty A. Effects of Bariatric Surgery on Human Small Artery Function. Journal of the American College of Cardiology. 2013;62(2):128-135.
  15. Gnacińska M, Małgorzewicz S, LysiakSzydłowska W. The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol Pol. 2010; 61: 36-41.
  16. Maahs D, Ogden L, Kinney G, Wadwa P, Snell-Bergeon J, Dabelea D, Hokanson J, Ehrlich J, Eckel R, Rewers M. Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification. Circulation. 2005;111(6):747-753.
  17. Norlander A, Madhur M, Harrison D. The immunology of hypertension. Journal of Experimental Medicine. 2017;215(1):21-33.
  18. Jamaluddin M, Weakley S, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. British Journal of Pharmacology. 2012;165(3):622-632.
  19. JUNG H, PARK K, CHO Y, CHUNG S, CHO H, CHO S, KIM S, KIM S, LEE H, PARK K. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovascular Research. 2006;69(1):76-85.
  20. Pashentseva AV. The role of leptin and resistin in the development of insulin resistance in patients with type 2 diabetes mellitus. Abstract. dis. Cand. honey. Science. Samara; 2012. 23p.
  21. Shankar A, Xiao J. Positive Relationship Between Plasma Leptin Level and Hypertension. Hypertension. 2010;56(4):623-628.
  22. Verbovaya NI, Kapralova IY, Verbovoi AF. Adiponectin, leptin and other indicators in patients with hypothyroidism. Ter. arch. 2014;10:33-35.
  23. de Faria A, Modolo R, Fontana V, Moreno H. Adipokines: Novel Players in Resistant Hypertension. The Journal of Clinical Hypertension. 2014;16(10):754-759.
  24. Koh K, Quon M, Lee S, Han S, Ahn J, Kim J, Chung W, Lee Y, Shin E. Efonidipine Simultaneously Improves Blood Pressure, Endothelial Function, and Metabolic Parameters in Nondiabetic Patients With Hypertension. Diabetes Care. 2007;30(6):1605-1607.
  25. Abdallah E, Waked E, Nabil M, El-Bendary O. Adiponectin and Cardiovascular Outcomes among Hemodialysis Patients. Kidney and Blood Pressure Research. 2012;35(4):247-253.
  26. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Practice & Research Clinical Endocrinology & Metabolism. 2014;28(1):119-130.
  27. UMEDA M, KANDA T, MURAKAMI M. Effects of Angiotensin II Receptor Antagonists on Insulin Resistance Syndrome and Leptin in Sucrose-Fed Spontaneously Hypertensive Rats.. Hypertension Research. 2003;26(6):485-492.
  28. Benson S, Pershadsingh H, Ho C, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery M, Kurtz T. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ-Modulating Activity. Hypertension. 2004;43(5):993-1002.
  29. Fogari R, Derosa G, Mugellini A. Effect of valsartan and eprosartan on adiponectin, leptin and insulin sensitivity in hypertensive obese patients. J Hypertens. 2006;24:258-264.
  30. Ihara, S., Shimamoto, K., Watanabe, H. et al. An α1-Receptor Blocker Reduces Plasma Leptin Levels in Hypertensive Patients with Obesity and Hyperleptinemia. Hypertens Res 29, 805-811 (2006).
  31. Zhao S, Wu Z. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clinica Chimica Acta. 2005;360(1-2):133-140.
  32. Koh K, Quon M, Han S, Chung W, Ahn J, Seo Y, Choi I, Shin E. Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia. Journal of the American College of Cardiology. 2005;45(10):1649-1653.